human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection Clinical Trials
2 recruitingDrug
Phase 12Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease
Parkinson Disease (PD)
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.90 enrolled1 locationNCT07166757
Recruiting
Phase 1
The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
Parkinson's Disease
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.12 enrolled1 locationNCT07080775